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Rosuvastatin alters the genetic 
composition of the human gut 
microbiome
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The gut microbiome contributes to the variation of blood lipid levels, and secondary bile acids are 
associated with the effect of statins. Yet, our knowledge of how statins, one of our most common drug 
groups, affect the human microbiome is scarce. We aimed to characterize the effect of rosuvastatin 
on gut microbiome composition and inferred genetic content in stool samples from a randomized 
controlled trial (n = 66). No taxa were significantly altered by rosuvastatin during the study. However, 
rosuvastatin-treated participants showed a reduction in the collective genetic potential to transport 
and metabolize precursors of the pro-atherogenic metabolite trimethylamine-N-oxide (TMAO, 
p < 0.01), and an increase of related metabolites betaine and γ-butyrobetaine in plasma (p < 0.01). 
Exploratory analyses in the rosuvastatin group showed that participants with the least favorable 
treatment response (defined as < median change in high-density/low-density lipoprotein (HDL/
LDL) ratio) showed a marked increase in TMAO-levels compared to those with a more favorable 
response (p < 0.05). Our data suggest that while rosuvastatin has a limited effect on gut microbiome 
composition, it could exert broader collective effects on the microbiome relevant to their function, 
providing a rationale for further studies of the influence of statins on the gut microbiome.
Originally discovered for their anti-microbial properties1, statins primarily reduce cholesterol levels and are 
first-line agents in the management of coronary artery disease (CAD)2. The use of statins has been increasing 
rapidly in recent decades, and they are now one of the most commonly prescribed group of drugs in Western 
countries2,3. The primary mode of action is inhibition of hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) 
reductase in the liver leading to decreased levels of low-density lipoprotein (LDL) cholesterol, but statins have 
other potential beneficial effects e.g., anti-inflammatory properties, inhibition of matrix metalloproteinases 
(MMPs) leading to plaque stabilization and inhibition of platelet aggregation4. The mechanisms underlying these 
pleiotropic effects are not completely understood and may not necessarily be mediated through HMG-CoA 
reductase inhibition5–7.
Changes in the composition and function of gut microbiome have been implicated in the pathogenesis of a 
wide range of human conditions including various systemic disorders like cardiometabolic and autoimmune 
disorders8,9. In cardiovascular disease (CVD), the gut microbiota-dependent metabolite trimethylamine-N-oxide 
(TMAO) and related metabolites, has been associated cardiovascular risk8,9. The large intra-individual variation 
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of the microbiome could potentially also contribute to variation in both treatment-responses and side effects10, 
and as shown in oncological studies, the microbiome can be used to identify patients responding to treatment11. 
Yet, our knowledge of how non-antibiotic pharmacological agents affect the microbiome and related metabolites 
is scarce. In cross-sectional studies12, and a few randomized controlled trials (e.g. metformin and proton pump 
inhibitors [PPIs]) drugs profoundly affect the gut microbiome and hence potentially its metabolic capacity13,14. 
Interestingly, statins rank second (after PPIs) among drug classes associated with microbiota composition12, but 
so far the ability of statins to modulate the gut microbiome has, to the best of our knowledge, not been tested in 
randomized controlled trials (RCT).
Some intestinal effects of statins have been observed, including an association with reduced risk of 
Clostridioides difficile (formerly Clostridium difficile) infection6, and colorectal cancer in patients with inflam-
matory bowel disease15. In addition, in one study, circulating levels of the gut microbial metabolites secondary 
bile acids predicted the effect on cholesterol profile7. Lastly, the gut microbiota has been shown to contribute to a 
substantial proportion of the variation of blood lipids, especially high-density lipoprotein (HDL)16.
In the present study we aimed to investigate the effect of statins on the gut microbiota using stool samples col-
lected from a randomized placebo-controlled double-blinded trial of rosuvastatin treatment in females undergo-
ing coronary angiography for chest pain but with no or minimal CAD (ClinicalTrials.gov-ID: NCT01582165)17.
patients and Methods
Trial design and participants. Participants were recruited, and the study was performed as previously 
described17. In short; study participants were recruited at Oslo University Hospital Rikshospitalet, a tertiary care 
center in Oslo, Norway between June 2012 and December 2015. Female patients aged 30–70 years with suspected 
ischemic chest pain referred for coronary angiography as part of a diagnostic workup were eligible for inclusion 
in the study if bicycle ergometry gave positive or equivocal findings.
Overall, 66 participants with normal or near-normal coronary angiograms were included in the study and 
randomized 1:1 to rosuvastatin 20 mg daily or placebo for 6 months in a double-blinded fashion using a comput-
erized procedure. Stool sampling was part of the study program from included participant number 7.
Ethics. The study was performed in accordance with Good Clinical Practice and the declaration of Helsinki. 
Written informed consent was obtained from all study participants prior to heart catheterization. Ethical approval 
was obtained from Regional Committee for Medical and Health Research Ethics in South-Eastern Norway 
(reference number 2012/286b & 2011/1600), and the primary study was registered at ClinicalTrials.gov (NCT 
01582165) and EUDRACT (2011- 002630-39.3tcAZ).
Sample collection. Demographic data, medical history and medication were collected at baseline as pre-
viously described17. Additional dietary data were collected using a questionnaire, as previously described18, and 
participants were instructed not to change diet during the study course. Stool samples were collected at base-
line, after four weeks and at study end (Supplementary Fig. S1). All participants used a standardized collection 
device for stool sampling after voiding19, and Stool Collection Tubes with Stool DNA Stabilizer (Stratec Molecular 
GmbH, Berlin, Germany) was used for transportation by mail to the study center, and samples with >72 h from 
collection to freezer were excluded (time limit according to the manufacturer). Samples were frozen at −80 °C on 
arrival. None of the included participants had a history of bowel resection, gastrointestinal stoma or specific diets 
(e.g. vegan, vegetarian, gluten free and milk free diets). If participants reported to have used antibiotics during 
the four weeks prior to sampling, the sample was collected and sequenced but not included in the analyses. An 
overview of stool samples not included in the analyses are given in Supplementary Table S1. Peripheral venous 
blood was collected using pyrogen-free tubes with EDTA as the anticoagulant. Tubes were immediately immersed 
in melting ice and centrifuged within 30 min at 2000 × g for 20 min to obtain platelet-poor plasma. All samples 
were stored at −80 °C until being analyzed. Routine blood samples were analyzed using commercial methods. 
Routine biochemistry was performed at the Department of Medical Biochemistry and extracted from hospital 
data records. Estimated glomerular filtration rate (eGFR) was calculated according to Levey et al.20.
DNA extraction, sequencing and post-processing. DNA was extracted using the PSP Spin Stool DNA 
Plus Kit (Stratec Molecular GmbH, Berlin, Germany), according to the manufacturer instructions. Library prepa-
rations were performed in accordance with a well-established protocol21. Libraries were constructed from PCR 
amplicons of the V3-V4 region of the 16S rRNA gene generated using a unique combination of dual-indexing 
primers (319F/806R) and Phusion High-Fidelity PCR Master mix with HF buffer (Thermo Fisher Scientific, 
Waltham, MA, USA). PCR products were normalized using the SequalPrep Normalization Plate Kit (Thermo 
Fisher Scientific), before pooling and sequencing was performed at the Norwegian Sequencing Centre (Oslo, 
Norway) on Illumina MiSeq using the v3 kit (San Diego, CA, USA). The Quantitative Insights Into Microbial 
Ecology (QIIME) pipeline version 1.9.122 was used for post-sequencing processing and closed reference oper-
ational taxonomic unit (OTU) mapping to the Silva database (version 128, reference OTUs pre-clustered at 
97% sequence similarity) was performed using SortMeRNA version 2.0 through QIIME. OTUs with a number 
of sequences < 0.005% of the total number of mapped sequences were discarded as recommended23, and cal-
culations of rarefied alpha diversity (Chao1 bacterial richness estimate (Chao1), Shannon diversity index and 
Phylogenetic Diversity) were performed in QIIME The samples were rarefied (subsampled) to an OTU count of 
11820 per sample, and all further analyses were performed on the rarefied dataset, and prediction of gut microbial 
functional profiles based on the 16S rRNA sequencing data were performed using Tax4Fun version 0.3.124.
Metabolite measurement. Serum levels of betaine, trimethylamine-N-oxide (TMAO), carnitine, 
γ-butyrobetaine and choline were quantified by high performance liquid chromatography as previously 
described25. In summary, we used stable isotope dilution liquid chromatography–tandem mass spectrometry 
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(LC/MS/MS), where we monitored TMAO, choline, betaine, carnitine and γ-butyrobetaine in positive liq-
uid chromatography–tandem mass spectrometry (MRM) MS mode and the characteristic precursor–product 
ion transitions: m/z 76→58, m/z 104→60, m/z 118→58, m/z 162→103 and m/z 146→87, respectively, was 
used. Before protein precipitation, internal standards were added to the plasma samples. The internal stand-
ards (TMAO-trimethyl-d9 (d9-TMAO), choline-trimethyl-d9 (d9-choline), L-carnitine-d3 (methyl-d3), 
betaine-trimethyl-d9-methylene-d2 (d11-betaine) and γ-butyrobetaine N-(carboxypropyl)-N,N,N,trimethyl-d9) 
were similarly monitored in MRM mode at m/z 85→66, m/z 113→69, m/z 165→103 and m/z 129→66 and m/z 
155→87, respectively. To prepare the calibration curves for the quantification of plasma analyte, various con-
centrations of carnitine, betaine, TMAO, choline and γ-butyrobetaine standards and a fixed amount of internal 
standards was spiked into 4% bovine serum albumin25. All the stable isotope-labelled internal standards were pur-
chased from Cambridge Isotope Laboratories, Inc. (Andover, MA, USA) except for carnitine and γ-butyrobetaine 
which were purchased from CDNI Isotopes (Quebec, Canada).
Power estimates. We had 80% power to detect a ≥ 50% change in relative abundance of bacterial taxa at the 
genus level of ≥0.5% mean relative abundance, and a ≥ 16% change in alpha diversity, caused by rosuvastatin.
Statistical analysis. Comparison of categorical variables was performed using the Chi-square test. 
Distribution of continuous variables were evaluated using histograms and Students t-test and the Mann-Whitney 
U test was used as appropriate. The Mann-Whitney U test was used to compare the differences in the change of 
taxa on the genus level and KEGG Orthologs between study groups in the initial screening, and these calculations 
were performed in R version 3.4.1. Paired samples were subsequently compared using a general linear model 
ANOVA with repeated measures in SPSS Statistics for Macintosh, version 25 (IBM, Armonk, NY, USA) and 
p-values denoted PGLM, and non-normalized values were log-transformed before these analyses. For correlation 
analyses, the Spearman’s rank correlation test was utilized. False-discovery rate (FDR) was calculated according 
to Benjamini-Hochberg using R. FDR-corrected p-values were denoted QFDR. Unless otherwise stated, all other 
calculations were performed in SPSS.
Results
After exclusions for antibiotics use, failure to deliver adequate sample and post-sequencing quality control 
(Supplementary Table S1), microbiota data and plasma samples from baseline and study end were available from 
40 and 51 individuals, respectively (microbiota data: n = 20 in both the placebo and the rosuvastatin group; 
plasma: n = 25 in the placebo group and n = 26 in the rosuvastatin group). Demographics for randomized partic-
ipants with microbiota data available are given in Table 1. Randomized participants with and without microbiota 
data available did not differ at baseline (Supplementary Table S2).
Participants on rosuvastatin treatment showed an increase in gut microbial richness, but not statistically sig-
nificant compared with placebo (delta Chao1 8.6 [95% CI −27.7−44.8], PGLM = 0.22, Fig. 1). The treatment group 
did not show changes in other diversity measurements either, i.e. Phylogenetic Diversity and Chao1, compared 
to the placebo group (Fig. 1).
Compared with changes in the placebo-group, rosuvastatin had a very limited effect on the relative abundance 
of bacterial taxa at the genus level over the study period (Supplementary Table S3). Out of the 173 genera detected 
at baseline, 38 (22.0%) had a mean relative abundance ≥0.5%.
Despite the lack of significant compositional changes at the genus level, pharmacological treatment may 
induce more broad changes to several different taxonomic groups that share similar function. To investigate 
whether rosuvastatin affected the functional potential of the gut microbiota, we inferred microbial gene content 
in the samples based on the 16 S rRNA sequencing data. Out of the top 20 altered gene functions, the majority 
were un-related KEGG orthologs, however, four out of the 20 were related to cellular transport and metabolism 
along the choline/betaine-TMA metabolic pathway (P < 0.005, QFDR < 0.35, Supplementary Table S4), all show-
ing a reduction in the rosuvastatin group compared to placebo (Fig. 2). Furthermore, among all inferred genes 
we identified four additional functions related to the same pathway that were significantly altered, all showing 
reduction on rosuvastatin treatment (Supplementary Fig. S2).
We hypothesized that alterations in microbial functions and metabolites in the gut would be accompa-
nied by corresponding changes in peripheral blood. We therefore measured metabolites in plasma by liquid 
chromatography-tandem mass spectrometry. Betaine and γ-butyrobetaine, both metabolites related to the phos-
phatidylcholine/carnitine-TMA-TMAO pathway increased significantly in the rosuvastatin group compared to 
the placebo group (Fig. 3a, both PGLM < 0.01). Both carnitine and choline showed a trend towards an increase, but 
did not reach the significance threshold (Fig. 3a). However, TMAO was unaffected (Fig. 3b), also when adjusting 
for renal function (using eGFR, data not shown). There was no significant change in renal function in either of 
the study groups during follow-up (data not shown). Repeating the analyses with only those participants with 
microbiota-data available caused only minor changes: the increase of carnitine in the rosuvastatin group (n = 17) 
was significant compared to placebo (n = 16, PGLM = 0.044), while the results for betaine, γ-butyrobetaine and 
choline were similar (PGLM = 0.01, 0.007 and 0.084, respectively).
The relative abundance of the inferred genes shown in Fig. 2 did not correlate with plasma levels of the meas-
ured metabolites at baseline (data not shown). Changes occurring in plasma levels of betaine and γ-butyrobetaine 
during follow-up in the placebo group correlated with the change in the relative abundance of the genes encod-
ing for both glycine betaine transporter (rho = 0.58, p = 0.014 and rho = 0.54, p = 0.025, respectively) and 
trimethylamine-corrinoid protein co-methyltransferase (rho = 0.60, p = 0.011 and rho = 0.53, p = 0.029, respec-
tively) (Supplementary Table S5). In contrast, there were no significant correlations between changes in plasma 
and microbial genes in the rosuvastatin group (all p > 0.35, Supplementary Table S5).
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It is well known that the individual response to statin treatment shows large variations7. As statins primarily 
reduce low density lipoprotein (LDL) levels and the gut microbiota especially contribute to variation in HDL 
levels16, we used HDL to LDL ratio to evaluated treatment response, when performing exploratory analysis in the 
rosuvastatin group. Participants with a poor treatment response (defined as below the median change in HDL to 
LDL ratio) showed a significant increase in TMAO values, compared to the other participants (Fig. 3c).
Discussion
To our knowledge, this is the first study investigating the effects of a statin on the human gut microbiota using 
samples from a randomized controlled trial. We found that rosuvastatin in general had small effects on gut micro-
bial composition. On the other hand, rosuvastatin reduced the genetic potential of the gut microbiota to metab-
olize and transport several molecules along the choline/betaine-TMA metabolic pathway, with corresponding 
changes of related metabolites in plasma. Finally, although rosuvastatin did not induce changes in TMAO levels 
in the treatment group as a whole, those who had a poor improvement in HDL/LDL ratio had an increase in this 
pro-atherogenic gut-microbiota-derived metabolite indicating some relationship between statin effects and the 
gut microbiome.
Little is known about the direct effect of statins on the human gut microbiota, except for associations with 
overall bacterial composition in a population-based study12, and some differences between patients with and 
without normalization of blood lipid levels26. Herein, rosuvastatin treatment was associated with a trend towards 
increasing gut microbial richness, as reported in studies of atorvastatin-treated rats5, while studies in mice have 
been unable to detect changes in fecal microbial diversity after rosuvastatin treatment27,28. In contrast to previ-
ous association studies in humans, our randomized placebo-controlled trial showed in general only modest and 
non-significant effects of statin intervention (i.e., rosuvastatin) on gut microbiome composition. Studies in mice 
have shown a similar very modest impact of rosuvastatin on fecal bacterial composition27,28, and at physiologically 
relevant concentrations rosuvastatin has little impact on bacterial growth in vitro28. However, the rather small 
sample size of our study makes it under-powered to detect subtle changes in relative abundance in general and 
also for broader changes in low-abundant taxa.
Placebo Rosuvastatin
p value nan = 20 n = 20
Age, years 51.5 (±8.7) 59.3 (±6.9) 0.003
Sex (female) 20 (100) 20 (100) 1.000
Current or former smoker 13 (65) 13 (65) 1.000
Body mass index, kg/m2 28.3 (±5.1) 25.2 (±3.8) 0.052b
Hypertension 4 (20) 5 (25) 0.500
Diabetes mellitus type 2 0 (0) 0 (0) —
Family history of CAD 16 (80) 13 (65) 0.240
Medication
ACEi/ARB 3 (15) 1 (5) 0.302
Beta blockers 8 (40) 5 (25) 0.250
Calcium-channel blocker 1 (5) 1 (5) 0.756
Aspirin 14 (70) 13 (65) 0.500
Proton pump inhibitors 3 (15) 0 (0) 0.115
Biochemistry
Total cholesterol, mmol/L 6.0 (±1.5) 5.9 (±1.0) 0.923
LDL, mmol/L 4.0 (±1.4) 3.7 (±0.9) 0.422
HDL, mmol/L 1.5 (±0.6) 1.9 (±0.4) 0.035
Triglycerides, mmol/L 1.8 (±0.9) 1.3 (±0.6) 0.038
Hemoglobin, g/dL 14.1 (±0.7) 13.9 (±0.8) 0.485
Creatinine, µmol/L 65.5 (±11.4) 64.6 (±7.0) 0.765
Total bilirubin, mg/dL 6.3 (±2.4) 7.5 (±5.0) 0.362 18/19
AST, U/L 22.4 (±6.7) 25.5 (±5.9) 0.134
ALT, U/L 21.1 (±11.3) 22.4 (±7.5) 0.674 19/20
ALP, U/L 65.6 (±18.5) 62.0 (11.7) 0.481 17/19
HbA1c, % 5.7 (±0.4) 5.6 (±0.4) 0.510
CRP, mg/L 4.0 (±3.7) 2.3 (±2.1) 0.099b
Table 1. Baseline characteristics of randomized patients with microbiota data available from baseline and study 
end. Data are mean ± SD or n (%) values. aComplete data unless specified as n in placebo/rosuvastatin. bRight-
skewed data compared using the Mann-Whitney U test, all other variables compared using the Students t-test. 
ACEi, angiotensin-converting-enzyme inhibitor; ALP, alkaline phosphatase; ALT, alanine transaminase, ARB, 
angiotensin II receptor blockers; AST, aspartate transaminase; CAD, coronary artery disease; CRP, C-reactive 
protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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Figure 1. A trend towards increased gut microbial richness in participants receiving rosuvastatin. Participants 
on rosuvastatin treatment showed an increase in gut microbial richness (delta Chao1, paired t-test p = 0.04), 
but this increase was not statistically significant compared with the placebo group (PGLM = 0.22). A similar 
trend was detected for Phylogenetic diversity, while the change in Shannon diversity index was similar in the 
rosuvastatin and the placebo group. Data shown as mean ±95% CI. Paired t-test from baseline and study-
end within the same study group, denoted p. Comparison of change between the study groups using repeated 
measures ANOVA from baseline and study-end, denoted PGLM. Values at 4 weeks missing for n = 1 in each 
group.
Figure 2. Functions (KEGG Orthologs) in the gut microbiota related to cellular transport and metabolism 
along the choline/betaine-trimethylamine (TMA) metabolic pathway are affected by rosuvastatin treatment. 
Data are shown as mean ±95% CI. Repeated measures ANOVA from baseline and study-end, denoted PGLM. 
Values at four weeks missing for n = 1 in each group.
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Microbial influence on disease is perhaps more likely to relate to the collective function of the microbiome, 
rather than composition12. Whereas the overall effects of rosuvastatin on gut microbiome composition was poor, 
by inferring genetic content, we observed a reduction of several microbial genes encoding proteins related to the 
choline/betaine-TMA-pathway (overview in Supplementary Fig. S3). This could suggest that rosuvastatin inter-
feres with the microbiome’s ability to metabolize betaine and related metabolites, with corresponding changes 
in levels of metabolites in plasma, as we also observed. Of the measured metabolites in our study rosuvastatin 
had the greatest effect on betaine, which has previously been shown to inversely correlate with both triglycerides 
and non-HDL cholesterol29, and alleviate inflammation by lowering interleukin (IL)-1β secretion30. Increased 
betaine has also been associated with a reduced risk of both CVD and stroke31. The direct relationship between 
changes in plasma and gut during follow-up was however not immediately intuitive, since there was a correlation 
between changes in affected microbial genes and changes in metabolites during follow-up only in the placebo 
group. Although one should interpret result from such subgroup analyses with caution, it could be speculated that 
rosuvastatin somehow disrupts the steady-state of intestinal metabolism and/or absorption of these compounds. 
It is also possible that the increase could in part be explained by a more direct effect of statins on endogenous 
human sources31,32. However, bacterial and human metabolisms of these metabolites are intricate and far from 
completely understood33–35, as also illustrated in Supplementary Fig. S3, and experimental studies are needed to 
elucidate this further36.
Overall, however, rosuvastatin did not reduce TMAO in this study, but importantly, in the group with the 
least favorable effect of rosuvastatin on HDL/LDL-ratio, TMAO significantly increased during the study. The 
individual response to statin treatment in large clinical trials show large variations, and the number needed to 
treat (NNT) for rosuvastatin in women is 31 (i.e., one has to treat 31 women with rosuvastatin to prevent the first 
Figure 3. Changes in microbiome-related metabolites in peripheral blood during rosuvastatin treatment. (a) 
Rosuvastatin increase precursors of the microbiota dependent metabolite trimethylamine (TMA) in plasma. (b) 
TMA is metabolized to the pro-atherogenic metabolite trimethylamine-N-oxide (TMAO) in the liver, which 
is not affected by rosuvastatin. (c) Participants with the least favorable treatment response (defined as below 
median change in high density to low density lipoprotein (HDL/LDL) ratio) show a marked increase in TMAO 
levels compared to those with a more favorable response. All randomized participants with serum samples 
available were included in the analysis, irrespective of the availability of microbiome data. TMAO values 
missing for n = 2 in panel C. Data shown as mean ±95% CI. Repeated measures ANOVA, denoted PGLM.
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cardiovascular event or death)37. The gut microbiome also show large variation between people in the general 
population10,38, and probably contribute to the variation in treatment response of pharmacological agents, as 
recently show in several studies39–41, both directly my affecting drug metabolism36, through interaction with the 
immune system11, and possibly also effects on human metabolism. Taken together, it is tempting to hypothesize 
that this may contribute to some of the large variation in statin treatment response and pleiotropic effects of stat-
ins, as e.g., anti-inflammatory properties, stabilization of atherosclerotic plaques and inhibition of platelet aggre-
gation, as these are all associated with the betaine/choline-TMA-TMAO pathway8,9. Re-analyzing TMAO-related 
metabolites in material from previous statin-trials could be a logical next step.
In contrast to these observations, we were unable to detect any changes in different taxonomic groups induced 
by rosuvastatin treatment. This is a little surprising, given that statins in a recent large population-based cohort 
from Europe was the drugs with the second strongest association with over-all bacterial composition (measured 
by Bray-Curtis distance), somewhat less than PPI, but stronger than the association with antibiotics, although the 
explained variance of statin use on over-all bacterial composition in this study was only ~0.3%12. That rosuvas-
tatin show effect in the abundance of several genes, while not affecting abundance of individual taxa might seem 
contradictive, but could be explained by more subtle effect across multiple taxa that share the same genes. Our 
data could indicate that rosuvastatin affected the abundance of a genus in the Ruminococcaceae-family, which 
has previously been associated with the response to statin treatment26, but this change was not significant after 
adjusting for multiple testing.
Our study has some strengths and limitations that warrant further discussion. The randomized controlled 
study design is a major strength, as is the performance of coronary angiography in all participants. Still, inde-
pendent validation is necessary before a conclusion can be made. The main limitation of our study is the modest 
sample size with the corresponding loss of power. In addition, as in most microbiome studies there are some con-
cerns regarding multiple testing, which to some degree can be improved by adjusting p-values, as we did, although 
the ideal would be replication in separate cohorts. Dietary data were collected at baseline, but no in-depth survey 
(e.g. food-frequency or recall questionnaires) and all participants were instructed to avoid dietary changes during 
the study and none reported specific diets. Furthermore, inferring genetic content from 16S rRNA data has some 
limitations compared to shotgun sequencing although the correlation between these methods for human gastro-
intestinal samples is high (~0.85)24.
conclusion
We report data from a randomized placebo-controlled double-blinded trial of rosuvastatin treatment showing a 
minor effect of rosuvastatin on taxonomic composition of the gut microbiome. On the other hand, the collective 
genetic potential of the gut microbiome to transport and metabolize metabolites along the phosphatidylcholine/
carnitine-TMA-TMAO pathway was reduced in the rosuvastatin treated group, with a corresponding increase 
of several metabolites in plasma. Our findings suggest that statins could have a clinically relevant impact on the 
gut microbiome and provide a strong rationale for further and larger studies of the influence of statins on the gut 
microbiome, TMAO and related metabolites in the progression of CVD, and its influence on intra-individual 
treatment responses.
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